Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming.

Area of Science:

• Biochemistry
• Genetics
• Cell Biology

Background:

• Mitochondrial diseases present diverse clinical symptoms, even with similar mitochondrial DNA (mtDNA) mutations, due to varying mutant mtDNA levels.
• Current treatments for mitochondrial diseases lack definitive cures, necessitating novel therapeutic strategies.

Purpose of the Study:

• To investigate the therapeutic potential of low-dose resveratrol (RSV) in ameliorating mitochondrial dysfunction.
• To assess RSV's effect on cellular reprogramming and viability in patient-derived cells with mtDNA mutations.

Main Methods:

• Utilized patient-derived fibroblasts with homoplasmic mtDNA mutations.
• Assessed mitochondrial respiratory function.
• Evaluated cellular reprogramming efficiency into induced pluripotent stem cells (iPSCs).
• Measured cellular viability.

Main Results:

• Low-dose resveratrol (RSV) significantly improved mitochondrial respiratory dysfunction in fibroblasts with homoplasmic mtDNA mutations.
• RSV enhanced the efficiency of cellular reprogramming into iPSCs.
• Improved cellular viability was observed, partly contributing to enhanced reprogramming.

Conclusions:

• Resveratrol (RSV) demonstrates potential as a therapeutic agent for mitochondrial diseases.
• RSV may offer a novel treatment strategy by improving mitochondrial function and cellular health.